Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Marburg Virus
Research conducted at USA Scientific has provided new information about marburg virus
October 15th, 2008
"Virus-like particle (VLP)-based vaccines have the advantage of being morphologically and antigenically similar to the live virus from which they are derived, Expression of the glycoprotein and VP40 matrix protein from Lake Victoria marburgvirus (MARV) results in spontaneous production of VLPs in mammalian cells. Guinea pigs vaccinated with Marburg virus VLPs (mVLPs) or inactivated MARV (iMARV) develop homologous humoral and T-cell responses and are completely protected from a lethal homologous MARV challenge," investigators in the United States report. "To determine whether mVLPs based on the Musoke (aka Lake Victoria) isolate of MARV could broadly protect against...
Source: Vaccine Weekly (2008-10-15)
|
